12 Health Care Stocks Moving In Tuesday's After-Market Session
Portfolio Pulse from Benzinga Insights
In Tuesday's after-market session, health care stocks saw significant movements. Clover Health Investments, Inogen, and Nektar Therapeutics were among the top gainers, with their stocks rising due to the release of Q1 earnings. Conversely, Treace Medical Concepts, Inspire Medical Systems, and Semler Scientific led the losers, experiencing declines after their Q1 earnings reports. The movements reflect the market's reaction to the latest financial results.
May 07, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inspire Medical Systems' shares fell 15.87% to $206.67 following their Q1 earnings, with a market cap of $6.2 billion.
Inspire Medical Systems' significant stock price drop post-Q1 earnings indicates a negative market reaction, suggesting a bearish short-term outlook.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Semler Scientific's stock declined by 15.71% to $23.73 after its Q1 earnings, with a market cap of $166.8 million.
The decline in Semler Scientific's stock following Q1 earnings reflects investor concerns, likely leading to a negative short-term impact.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Treace Medical Concepts' stock declined by 34.1% to $7.34 after its Q1 earnings report, with a market cap of $454.6 million.
The sharp decline in Treace Medical Concepts' stock post-Q1 earnings suggests investor disappointment, indicating a bearish short-term trend.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Clover Health Investments' stock rose 14.9% to $0.85 after Q1 earnings, with a market cap of $421.4 million.
The positive reaction to Clover Health's Q1 earnings suggests investor confidence, likely leading to a short-term uptrend.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Inogen's shares increased by 13.97% to $8.32 following their Q1 earnings release, with a market cap of $195.9 million.
Inogen's stock rise post-Q1 earnings indicates strong market approval of their financial health, suggesting a bullish short-term outlook.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Nektar Therapeutics saw an 11.92% increase to $1.69 in its stock price, with a market cap of $310.3 million.
The significant rise in Nektar Therapeutics' stock following Q1 earnings reflects positive investor sentiment, likely leading to continued short-term gains.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90